CIPROFLOXACIN HYDROCHLORIDE | N021744 | DEPOMED INC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| N/A | Active | Jordan University of Science and Technology | 40 | 2010-06-28 → 2030-12-01 | |
| Early Phase 1 | Active | The Cleveland Clinic | 100 | 2011-02-11 → 2029-12 | |
| N/A | By Invitation | Ain Shams University | 108 | 2025-07-01 → 2030-08 | |
| Phase 2 | Not Yet Recruiting | Zealand University Hospital | 150 | 2027-03-01 → 2031-12-31 | |
| N/A | Not Yet Recruiting | Dow University of Health Sciences | 146 | 2026-09-23 → 2027-01-18 | |
| Phase 4 | Not Yet Recruiting | University of Illinois at Chicago | 236 | 2026-10-05 → 2029-08-03 | |
| Phase 4 | Recruiting | University of Alberta | 202 | 2021-06-28 → 2028-06-30 | |
| N/A | Recruiting | University Hospital, Ghent | 300 | 2016-08-19 → 2029-07-01 | |
| Phase 4 | Recruiting | University of Miami | 150 | 2026-08 → 2028-12 | |
| Phase 2 | Recruiting | Virginia Commonwealth University | 97 | 2025-03-07 → 2035-07-01 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
11 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Mar 3, 2011 | SUPPL -16 | View Letter (PDF) |
| Jan 4, 2011 | SUPPL -14 | View Letter (PDF) |
| May 13, 2009 | SUPPL -13 | View Letter (PDF) |
| Oct 23, 2008 | SUPPL -7 | View Letter (PDF) |
| Oct 23, 2008 | SUPPL -10 | View Letter (PDF) |
| Oct 8, 2008 | SUPPL -8 | View Letter (PDF) |
| Sep 6, 2007 | SUPPL -5 | View Letter (PDF) |
| Aug 2, 2007 | SUPPL -3 | View Letter (PDF) |
| Aug 21, 2006 | SUPPL -2 | View Letter (PDF) |
| May 20, 2005 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.